BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30593524)

  • 21. Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells.
    Salvatori L; Caporuscio F; Coroniti G; Starace G; Frati L; Russo MA; Petrangeli E
    J Cell Physiol; 2009 Jul; 220(1):35-44. PubMed ID: 19347870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma.
    Mizoshiri N; Shirai T; Terauchi R; Tsuchida S; Mori Y; Hayashi D; Kishida T; Arai Y; Mazda O; Nakanishi T; Kubo T
    Cell Oncol (Dordr); 2019 Dec; 42(6):861-871. PubMed ID: 31494861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.
    Zhao SJ; Jiang YQ; Xu NW; Li Q; Zhang Q; Wang SY; Li J; Wang YH; Zhang YL; Jiang SH; Wang YJ; Huang YJ; Zhang XX; Tian GA; Zhang CC; Lv YY; Dai M; Liu F; Zhang R; Zhou D; Zhang ZG
    Oncogene; 2018 Feb; 37(8):1049-1061. PubMed ID: 29084211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance.
    Dahn ML; Cruickshank BM; Jackson AJ; Dean C; Holloway RW; Hall SR; Coyle KM; Maillet H; Waisman DM; Goralski KB; Giacomantonio CA; Weaver ICG; Marcato P
    Mol Cancer Ther; 2020 May; 19(5):1110-1122. PubMed ID: 32156786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of dynamin-related protein 1 - dependent mitochondria fragmentation and suppression of osteosarcoma by cryptotanshinone.
    Yen JH; Huang HS; Chuang CJ; Huang ST
    J Exp Clin Cancer Res; 2019 Jan; 38(1):42. PubMed ID: 30691497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-derived osteosarcoma cells are resistant to methotrexate.
    Dos Santos Cavalcanti A; Meohas W; Ribeiro GO; de Sá Lopes AC; Gholamin S; Razavi M; Hanae Kasai Brunswick T; Avan A; Matheus Guimarães JA; Leite Duarte ME; Kahn SA
    PLoS One; 2017; 12(9):e0184891. PubMed ID: 28934267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
    Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
    Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
    You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
    Front Immunol; 2020; 11():1787. PubMed ID: 32973749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of estrogen receptors alfa and beta mRNA and alkaline phosphatase in the differentiation of osteoblasts from elderly postmenopausal women: comparison with osteoblasts from osteosarcoma cell lines.
    Chen FP; Hsu T; Hu CH; Wang WD; Wang KC; Teng LF
    Taiwan J Obstet Gynecol; 2006 Dec; 45(4):307-12. PubMed ID: 17175487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
    Thaler S; Schmidt M; Schad A; Sleeman JP
    Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gelsolin promotes cell growth and invasion through the upregulation of p-AKT and p-P38 pathway in osteosarcoma.
    Ma X; Sun W; Shen J; Hua Y; Yin F; Sun M; Cai Z
    Tumour Biol; 2016 Jun; 37(6):7165-74. PubMed ID: 26662962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulforaphene inhibits the progression of osteosarcoma via regulating FSTL1/NF-κB pathway.
    Zhang G; Jin C; Zhu Y; Fu F; Wang G; Li S
    Life Sci; 2020 Dec; 263():118485. PubMed ID: 33017573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
    Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
    Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
    McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
    Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Licochalcone A-Induced Apoptosis Through the Activation of p38MAPK Pathway Mediated Mitochondrial Pathways of Apoptosis in Human Osteosarcoma Cells In Vitro and In Vivo.
    Lin RC; Yang SF; Chiou HL; Hsieh SC; Wen SH; Lu KH; Hsieh YH
    Cells; 2019 Nov; 8(11):. PubMed ID: 31739642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis.
    Mahmood N; Arakelian A; Cheishvili D; Szyf M; Rabbani SA
    J Cell Mol Med; 2020 Sep; 24(18):10322-10337. PubMed ID: 32720467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.
    Manara MC; Valente S; Cristalli C; Nicoletti G; Landuzzi L; Zwergel C; Mazzone R; Stazi G; Arimondo PB; Pasello M; Guerzoni C; Picci P; Nanni P; Lollini PL; Mai A; Scotlandi K
    Mol Cancer Ther; 2018 Sep; 17(9):1881-1892. PubMed ID: 29959201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.
    Gleneadie HJ; Baker AH; Batis N; Bryant J; Jiang Y; Clokie SJH; Mehanna H; Garcia P; Gendoo DMA; Roberts S; Burley M; Molinolo AA; Gutkind JS; Scheven BA; Cooper PR; Parish JL; Khanim FL; Wiench M
    Cancer Lett; 2021 Mar; 501():172-186. PubMed ID: 33359448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.